{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T05:02:55Z","timestamp":1775624575966,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019081","name":"Science and Technology Program of Hunan Province","doi-asserted-by":"publisher","award":["2023SK4024"],"award-info":[{"award-number":["2023SK4024"]}],"id":[{"id":"10.13039\/501100019081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019081","name":"Science and Technology Program of Hunan Province","doi-asserted-by":"publisher","award":["2026JJ30152"],"award-info":[{"award-number":["2026JJ30152"]}],"id":[{"id":"10.13039\/501100019081","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.lungcan.2026.109369","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T15:41:27Z","timestamp":1772984487000},"page":"109369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immunotherapy rechallenge in Extensive-Stage small cell lung Cancer: A Real-World retrospective study"],"prefix":"10.1016","volume":"215","author":[{"given":"Jingyi","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4908-2099","authenticated-orcid":false,"given":"Yuling","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bolin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yini","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7078-7767","authenticated-orcid":false,"given":"Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109369_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18081\/2333-5106\/2025.1\/1","article-title":"International cancer burden analysis 2020\u20132024: GLOBOCAN-derived estimates of incidence and mortality for 30 malignancies in 190 geographic regions","volume":"13","author":"Begum","year":"2025","journal-title":"Am. J. Biomed."},{"key":"10.1016\/j.lungcan.2026.109369_b0010","first-page":"47","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J. Natl Cancer Cent."},{"key":"10.1016\/j.lungcan.2026.109369_b0015","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/CM9.0000000000002693","article-title":"Molecular classification of small cell lung cancer subtypes: Characteristics, prognostic factors, and clinical translation","volume":"137","author":"Guo","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.lungcan.2026.109369_b0020","article-title":"Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives","volume":"13","author":"Zhang","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2026.109369_b0025","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"IMpower133 Study Group, First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109369_b0030","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109369_b0035","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (Caspian): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2026.109369_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from Caspian","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2026.109369_b0045","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2026.109369_b0050","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line Serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial","volume":"328","author":"Cheng","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.lungcan.2026.109369_b0055","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jtho.2024.03.008","article-title":"Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (RATIONALE-312): a multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial","volume":"19","author":"Cheng","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109369_b0060","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1001\/jamaoncol.2024.5019","article-title":"Toripalimab plus chemotherapy as a first-line therapy for extensive-stage small cell lung cancer: the phase 3 EXTENTORCH randomized clinical trial","volume":"11","author":"Cheng","year":"2025","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2026.109369_b0065","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2025.0560","article-title":"Small cell lung cancer: a review","volume":"333","author":"Kim","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.lungcan.2026.109369_b0070","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251359057","article-title":"Advances in immuno-based and targeted therapies in extensive-stage small cell lung cancer","volume":"17","author":"Zou","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.lungcan.2026.109369_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107887","article-title":"Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients: a large French multicenter study","volume":"194","author":"Pons-Tostivint","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109369_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102775","article-title":"202P Clinical outcomes to second-line treatment, after failing chemoimmunotherapy, in ES-SCLC, in","volume":"9","author":"Andreas","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2026.109369_b0085","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s41571-025-01029-7","article-title":"Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer","volume":"22","author":"Tang","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109369_b0090","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.jtho.2018.08.2027","article-title":"Atezolizumab treatment beyond progression in advanced NSCLC: results from the randomized, phase III OAK study","volume":"13","author":"Gandara","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109369_b0095","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1002\/cncr.32190","article-title":"Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: a subgroup analysis of a randomized phase 3 clinical trial","volume":"125","author":"Haddad","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2026.109369_b0100","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1001\/jamaoncol.2017.1588","article-title":"Nivolumab for patients with advanced melanoma treated beyond progression: Analysis of 2 phase 3 clinical trials","volume":"3","author":"Long","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2026.109369_b0105","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1093\/annonc\/mdx518","article-title":"Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: Post-progression outcomes from the phase II IMvigor210 study","volume":"28","author":"Necchi","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109369_b0110","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.3390\/cancers17132256","article-title":"Redefining the fight against SCLC: Standards, innovations, and new horizons","volume":"17","author":"Kemper","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2026.109369_b0115","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1245\/s10434-025-17327-4","article-title":"Updates on the version 9 American Joint Committee on Cancer staging system for lung cancer","volume":"32","author":"Asamura","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.lungcan.2026.109369_b0120","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109369_b0125","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jama.2024.21972","article-title":"World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human participants","volume":"333","author":"World Medical Association","year":"2025","journal-title":"JAMA"},{"issue":"Supplement 1","key":"10.1016\/j.lungcan.2026.109369_b0130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0025-7753(05)72209-0","article-title":"STROBE group, Estudios epidemiol\u00f3gicos (STROBE)","volume":"125","author":"Fern\u00e1ndez","year":"2005","journal-title":"Med. Clin. (Barc.)"},{"key":"10.1016\/j.lungcan.2026.109369_b0135","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","article-title":"D\u2019Amico, et al., small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"19","author":"Ganti","year":"2021","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.lungcan.2026.109369_b0140","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1158\/1078-0432.CCR-22-0657","article-title":"Systemic and oligo-acquired resistance to PD-(L)1 blockade in lung cancer","volume":"28","author":"Schoenfeld","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109369_b0145","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.1200\/JCO.2025.43.16_suppl.8013","article-title":"Safety and efficacy of lurbinectedin plus atezolizumab as second-line treatment for advanced small-cell lung cancer: results of the 2SMALL phase 1\/2 study (NCT04253145)","volume":"43","author":"Ponce Aix","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109369_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102249","article-title":"Beyond first-line therapy: Efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression","volume":"52","author":"Peng","year":"2025","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.lungcan.2026.109369_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.108021","article-title":"Continuing immune checkpoint inhibitors after progression: Real-world patterns of care and outcomes in second-line treatment for extensive-stage small-cell lung cancer","volume":"199","author":"Zhang","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109369_b0160","article-title":"Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lungcan.2026.109369_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114372","article-title":"The efficacy of ICIs rechallenge in advanced small cell lung cancer after progression from ICIs plus chemotherapy: a real-world study","volume":"152","author":"Liu","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.lungcan.2026.109369_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108786","article-title":"Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer","volume":"209","author":"Andreas","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109369_b0175","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.2217\/imt-2023-0073","article-title":"Real-world utilization of immune checkpoint inhibitors in extensive stage small-cell lung cancer in community settings","volume":"15","author":"Zu","year":"2023","journal-title":"Immunotherapy"},{"key":"10.1016\/j.lungcan.2026.109369_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103502","article-title":"Efficacy and safety of tislelizumab plus anlotinib and irinotecan as second-line treatment for extensive-stage small cell lung cancer: a single-arm, open-label, phase II trial","volume":"88","author":"Chen","year":"2025","journal-title":"Eclinicalmedicine"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T04:24:14Z","timestamp":1775622254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226004307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":36,"alternative-id":["S0169500226004307"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109369","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy rechallenge in Extensive-Stage small cell lung Cancer: A Real-World retrospective study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109369","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109369"}}